Date: 2013-01-08
Type of information: R&D agreement
Compound: CNS-targeted liposomal drug delivery system (G-Technology)
Company: to-BBB (The Netherlands) ALS Therapy Development Institute (USA)
Therapeutic area: Neurodegenerative diseases - Neuromuscular diseases
Type agreement: R&D
Action mechanism:
Disease: amyotrophic lateral sclerosis
Details: The ALS Therapy Development Institute (ALS TDI) has entered into a new collaboration with to-BBB to investigate potential treatments for amyotrophic lateral sclerosis. Under the terms of the agreement, ALS TDI will use to-BBB\'s CNS-targeted liposomal drug delivery system (G-Technology) as a tool to safely enhance the transport of several different compounds to the brain across the blood-brain barrier. The institute will screen compounds in a preclinical model of amyotrophic lateral sclerosis to determine if the enhanced formulation of the proposed treatments have an improved effect on disease course. The collaborators have been working together since early in 2012, designing and completing proof-of-concept experiments confirming that to-BBB\'s G-Technology indeed accomplishes sustained and effective delivery og drugs to the CNS in the SOD1 preclinical model of amyotrophic lateral sclerosis.
Financial terms:
Latest news:
